Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (AKBA) will hold investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
CEO John P. Butler, Chief R&D and Medical Officer Dr. Steven Burke, and Chief Financial and Chief Business Officer Erik Ostrowski will participate in one-on-one meetings. Management will discuss the company's commercial products and clinical-stage pipeline assets for rare kidney diseases.
Akebia Therapeutics (AKBA) announced presentations on vadadustat and its rare kidney disease pipeline at ASN Kidney Week, October 21–25, 2026. The meeting takes place in Denver. U.S. Renal Care will present VOICE trial results on October 23, evaluating the safety of three-times-weekly vadadustat versus an erythropoiesis-stimulating agent in patients receiving in-center hemodialysis.
Akebia-supported posters cover preclinical praliciguat research in focal segmental glomerulosclerosis, a kidney disease, and its Phase 2 trial in that condition. Another covers the Phase 2 ebribafusp alfa trial in complement-mediated kidney diseases. Vafseo (vadadustat) posters address hospitalization costs versus darbepoetin alfa using Phase 3 INNO2VATE data, cardiovascular events with once-daily versus three-times-weekly dosing, and the relationship between peak vadadustat exposure and cardiovascular events.
Akebia Therapeutics (AKBA) granted a newly hired employee options to purchase 8,400 common shares on September 30, 2026, as an employment inducement.
The options have an exercise price of $0.92 per share, equal to the stock's closing price on the grant date. They vest over four years: 25% on the grant's first anniversary and the remaining 75% quarterly thereafter, subject to continued service. Each option has a 10-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4) and is subject to Akebia's inducement award program and stock option agreement.
Akebia Therapeutics (AKBA) has dosed the first patient in an open-label Phase 2 basket trial of investigational drug ebribafusp for rare complement-mediated kidney diseases.
The study evaluates patients with IgA nephropathy, lupus nephritis and C3 glomerulopathy and is expected to enroll up to 30 participants. Ebribafusp, a next-generation anti-C3d factor H fusion protein, is designed to inhibit complement activation in kidney tissue without blocking the complement system in blood. Patients will receive once-weekly subcutaneous dosing for 26 weeks, followed by a long-term extension for responders, with initial data expected in 2027.
The primary endpoint is incidence of adverse events, and secondary endpoints include changes in proteinuria (UPCR), kidney function (eGFR) and pharmacokinetics, along with blood and urine complement biomarkers.
Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026. The option covers an aggregate of 8,400 shares of Akebia common stock at an exercise price of $0.92 per share, equal to the closing price on the grant date. The award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service, and have a 10-year term under Akebia’s inducement award program and stock option agreement.
Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and CFO/CBO Erik Ostrowski will participate in one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston, held September 8–10, 2026. Management plans to discuss Akebia’s commercial kidney disease products and its pipeline of clinical-stage programs.
Akebia Therapeutics (Nasdaq: AKBA) reported Q2 2026 total revenues of $49.1 million, down from $62.5 million a year earlier, as Auryxia revenues fell to $25.5 million amid generic competition. Vafseo net product revenues grew to $21.3 million, up 34% sequentially and from $13.3 million in Q2 2025.
More than 10,500 patients were on Vafseo in Q2, a 41% increase from Q1, with prescribers rising to about 1,200. Akebia reported a net loss of $8.9 million versus net income of $0.2 million a year ago, and held $155.5 million in cash and equivalents at June 30, 2026, which it believes funds operations for at least two years. The company advanced its rare kidney disease pipeline with a Phase 2 basket trial of ebribafusp and continued a Phase 2 trial of praliciguat. An interim analysis of the VOICE trial showed statistically significant improved safety outcomes for Vafseo versus an ESA on a composite of all-cause mortality and hospitalization, and Akebia strengthened Vafseo intellectual property with additional Orange Book–listed patents extending coverage out to 2036.
Akebia Therapeutics (Nasdaq: AKBA) granted stock options to two newly hired employees on July 31, 2026, covering an aggregate 61,000 shares of common stock as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.32 per share, equal to the closing price on the grant date.
The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service. Each option has a 10-year term and is granted under Akebia’s inducement award program and a related stock option agreement.
Akebia Therapeutics (Nasdaq: AKBA) has initiated an open-label Phase 2 basket trial of ebribafusp, a next-generation complement inhibitor, in rare complement-mediated kidney diseases: IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). The study will evaluate safety, efficacy, and pharmacokinetics of once-weekly subcutaneous dosing over 26 weeks in up to 30 patients, followed by a long-term extension for responders.
The trial’s primary endpoint is incidence of adverse events, with secondary endpoints including changes in proteinuria (UPCR), kidney function (eGFR), and pharmacokinetics, plus blood and urine complement biomarkers. A prior Phase 1 study in healthy volunteers showed weekly 450 mg dosing achieved target tissue exposures without inhibiting complement in blood and was generally well-tolerated. Akebia acquired global rights to ebribafusp from Q32 Bio in November 2025 and expects initial Phase 2 data in 2027 (NCT06419205).
Akebia Therapeutics (Nasdaq: AKBA) will release its second quarter 2026 financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, after the market close.
The company will host a conference call the same day at 4:30 p.m. EDT, accessible by phone using passcode 4727037 or via live webcast and archived replay in the Investors section of its website.